Traumatic Brain Injury Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Traumatic Brain Injury Treatment Landscape. Click here to read more @ Traumatic Brain Injury Pipeline Outlook
Key Takeaways from the Traumatic Brain Injury Pipeline Report
In June 2025, Hope Biosciences announced a study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure, neurocognitive/functional outcomes, and neuroinflammation after traumatic brain injury.
In June 2025, Merz Pharmaceuticals GmbH conducted a study is to determine whether a single treatment with administration of 400 Units NT 201 (botulinum toxin) is superior to placebo (no medicine) for the treatment of lower limb spasticity caused by stroke or traumatic brain injury (Main Period). Participants will be assigned to the treatment groups by chance and neither the participants nor the research staff who interact with them will know the allocation.
In June 2025, Ipsen organized a study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.
DelveInsight's Traumatic Brain Injury pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Traumatic Brain Injury treatment.
The leading Traumatic Brain Injury Companies such as Oragenics, Inc, SHINKEI Therapeutics, Inc, AlzeCure, Algernon Pharmaceutical, Mitochon Pharmaceuticals, Hoth Therapeutics, Biomed Industries, Inc, BioArctic, Tiziana Life Sciences, TikoMed AB, Levolta Pharmaceuticals, Inc, Boulder BioScience, LLC, International Stem Cell Corporation, Revalesio Corporation, Teleport Pharmaceuticals and others.
Promising Traumatic Brain Injury Pipeline Therapies such as Flortaucipir F18, NE3107, Amantadine Hydrochloride, VAS203, SB623 cells, Rivastigmine, VAS203, Dexanabinol and others.
Discover groundbreaking developments in Traumatic Brain Injury Therapies! Gain in-depth knowledge of key Traumatic Brain Injury Emerging Drugs, and market opportunities @ Traumatic Brain Injury Clinical Trials Assessment
Traumatic Brain Injury Emerging Drugs Profile
ONP-002: Oragenics, Inc.
ONP-002 is a First-in-Class Enantiomeric-Neurosteroid being developed for the treatment of mild Traumatic Brain Injury (mTBI) aka concussion. ONP-002 diffuses intracellularly to induce steroid receptors found in neurons, glia, and the endothelium of the blood brain-barrier. The induction of the ONP-002 receptors activates multiple gene response elements leading to the production of mRNA transcripts and subsequently proteins that reduce inflammation, oxidative stress, and swelling. In addition, ONP-002 induces macro-autophagy to reduce the build-up of extra- and intra-cellular debris that can cause chronic neurological diseases associated with dementia. Currently, the drug is in the Phase II stage of its development for the treatment of Traumatic Brain Injury.
MR-301: SHINKEI Therapeutics, Inc
MR-301 – Amantadine HCl Intravenous (IV) Solution is SHINKEI's most advanced program. Amantadine HCl is one of the most commonly prescribed off-label medications for patients with prolonged disorders of consciousness after TBI. Amantadine HCl increases dopamine availability in the synapse by inhibiting the activation of dopaminergic receptors. Amantadine HCl has been approved as a prescription oral product in the U.S since 1966 and, as such, has a long history of safe use in the U.S. and globally. Preliminary studies in preclinical models and patients with TBI have suggested that amantadine may promote functional recovery with high levels of safety. Currently, the drug is in Phase II stage of its development for the treatment of Traumatic Brain Injury.
ACD 856: AlzeCure
ACD 856 is a small molecule, positive allosteric modulator of Trk receptors, which mediate the effects of BDNF, NGF, and other neurotrophic factors. ACD856 increases the kinase activity of Trk receptors and enhances the effects of BDNF or NGF on survival, neuronal function, and synaptic plasticity. This is intended to make up for loss of BDNF and NGF signaling that occurs in AD. This compound is taken orally. The compound improves mitochondrial function and increases BDNF expression in cells, and shows antidepressant activity in mice. Currently, the drug is in Phase I stage of its development for the treatment of Traumatic Brain Injury.
AP-188: Algernon Pharmaceutical
AP-188 (N,N-Dimethyltryptamine, or DMT) is a potential treatment for stroke and traumatic brain injury (TBI) recovery. DMT is a naturally occurring compound that is part of the tryptamine family, which also includes psilocybin and psilocin. DMT is naturally occurring and found in plants and animals and is expressed naturally in humans in times of great physiological stress, including cardiac arrest and childbirth. It is assumed to have roles in cell protection, regeneration, and immunity as well. The drug is a sigma receptor agonist, and some evidence points to sigma receptor binding as a critical factor in the drug's protective actions. Psychedelic drugs as a class have also demonstrated an ability to promote neuritogenesis both in vivo and in vitro. The effects are believed to be through agonism of the 5-HT2A receptor, although other receptors, including sigma, may be involved. DMT increases expression of Brain Derived Neurotropic Factor (BDNF), which promotes neuroplasticity: a key factor in the brain's ability to form and reorganize synaptic connections, which are needed for healing following a brain injury. DMT is also known to bind to a number of other receptors, including various 5-HT, dopamine, adrenergic, and trace amine receptors. Currently, the drug is in Phase I stage of its development for the treatment of Traumatic Brain Injury.
The Traumatic Brain Injury Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Traumatic Brain Injury with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Traumatic Brain Injury Treatment.
Traumatic Brain Injury Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Traumatic Brain Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Traumatic Brain Injury market
Stay informed about the Traumatic Brain Injury pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Traumatic Brain Injury Unmet Needs
Traumatic Brain Injury Companies
Oragenics, Inc, SHINKEI Therapeutics, Inc, AlzeCure, Algernon Pharmaceutical, Mitochon Pharmaceuticals, Hoth Therapeutics, Biomed Industries, Inc, BioArctic, Tiziana Life Sciences, TikoMed AB, Levolta Pharmaceuticals, Inc, Boulder BioScience, LLC, International Stem Cell Corporation, Revalesio Corporation, Teleport Pharmaceuticals and others.
Traumatic Brain Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Traumatic Brain Injury Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Transform your understanding of the Traumatic Brain Injury Pipeline! See the latest progress in drug development and clinical research @ Traumatic Brain Injury Market Drivers and Barriers, and Future Perspectives
Scope of the Traumatic Brain Injury Pipeline Report
Coverage- Global
Traumatic Brain Injury Companies- Oragenics, Inc, SHINKEI Therapeutics, Inc, AlzeCure, Algernon Pharmaceutical, Mitochon Pharmaceuticals, Hoth Therapeutics, Biomed Industries, Inc, BioArctic, Tiziana Life Sciences, TikoMed AB, Levolta Pharmaceuticals, Inc, Boulder BioScience, LLC, International Stem Cell Corporation, Revalesio Corporation, Teleport Pharmaceuticals and others.
Traumatic Brain Injury Pipeline Therapies- Flortaucipir F18, NE3107, Amantadine Hydrochloride, VAS203, SB623 cells, Rivastigmine, VAS203, Dexanabinol and others.
Traumatic Brain Injury Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Traumatic Brain Injury Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Research-Access the Full Traumatic Brain Injury Pipeline Analysis Today! @ Traumatic Brain Injury Drugs and Companies
Table of Contents
Introduction
Executive Summary
Traumatic Brain Injury: Overview
Pipeline Therapeutics
Therapeutic Assessment
Traumatic Brain Injury– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Drug Name: Company Name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ONP-002: Oragenics, Inc.
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ACD 856: AlzeCure
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Traumatic Brain Injury Key Companies
Traumatic Brain Injury Key Products
Traumatic Brain Injury- Unmet Needs
Traumatic Brain Injury- Market Drivers and Barriers
Traumatic Brain Injury- Future Perspectives and Conclusion
Traumatic Brain Injury Analyst Views
Traumatic Brain Injury Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/traumatic-brain-injury-tbi-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
9 hours ago
- National Post
KARL STORZ Unifies Canada, US, and Veterinary Organizations to Form North America Region Led by Sonal Matai
Article content New organizational structure will drive commercial growth, innovation, and overall business performance. Article content EL SEGUNDO, Calif. — KARL STORZ, a family-owned medical technology company headquartered in Tuttlingen, Germany, today announced the creation of a North America region that unifies its US, Canada, and Veterinary businesses under the leadership of Sonal Matai. Article content Matai joined KARL STORZ in 2022 and was appointed to lead KARL STORZ United States in early 2024. As President of North America, Matai will now oversee key functions such as commercial operations, research and development, and manufacturing under a unified leadership structure for the region. Article content The formation of KARL STORZ North America reflects the company's commitment to enhancing operational efficiency, service, and value to its customers across a broader geographic footprint. Article content 'After 80 years, KARL STORZ's mission remains the same – to improve patient lives,' said Matai, President of KARL STORZ North America. 'The decision to unify our businesses across North America underscores our commitment to our customers and their evolving needs in patient care. This is an exciting opportunity to leverage exceptional talent from both countries, which will only strengthen our ability to bring solutions to market with greater speed and agility.' Article content Effective today, KARL STORZ North America encompasses six locations in the US and a Canadian and Veterinary hub in Mississauga, Ontario, a region recognized for its booming medical technology sector. Changes to the organizational structure will cause no anticipated disruption to services, product availability, or customer support. Article content About KARL STORZ Article content KARL STORZ is an innovative leader in endoscopic technology and surgical imaging solutions across virtually all surgical specialties. Its integrated OR solutions, including advancements in digital surgery, enhance collaboration to improve clinical efficiency and outcomes inside the hospital and across other sites of care. With subsidiaries around the world, KARL STORZ is a family-owned company based in Germany that designs, engineers, manufactures, and markets all its products with an emphasis on visionary design, precision craftsmanship, and clinical effectiveness. For more information, visit Article content Article content Article content
Globe and Mail
10 hours ago
- Globe and Mail
Neurofibromatoses Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Neurofibromatoses Pipeline Insight, 2025 ' report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Neurofibromatoses pipeline landscape. It covers the Neurofibromatoses pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neurofibromatoses pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Neurofibromatoses Treatment Landscape. Click here to read more @ Neurofibromatoses Pipeline Outlook Key Takeaways from the Neurofibromatoses Pipeline Report In June 2025, Healx Limited announced a phase 2 study in 20 participants. The study will assess the tolerability and efficacy of HLX-1502 in participants with NF1 16 years of age or older with progressive and/or symptomatic PN. In June 2025, Novartis Pharmaceuticals conducted a study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib. DelveInsight's Neurofibromatoses pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Neurofibromatoses treatment. The leading Neurofibromatoses Companies such as Shanghai Fosun Pharmaceutical, Healx Limited, Pasithea Therapeutics Corp., NFlection Therapeutics Inc., Infixion Bioscience and others. Promising Neurofibromatoses Pipeline Therapies such as trametinib, dabrafenib, bevacizumab, everolimus, Siltuximab, and others. Discover groundbreaking developments in Neurofibromatoses Therapies! Gain in-depth knowledge of key Neurofibromatoses emerging drugs, and market opportunities @ Neurofibromatoses Clinical Trials Assessment Neurofibromatoses Emerging Drugs Profile FCN-159: Shanghai Fosun Pharmaceutical FCN-159 is a novel, proprietary and highly potent inhibitor of mitogen-activated protein kinase kinase enzymes (MEK). It is being developed by Fochon as a monotherapy and in combination to treat solid tumors. MEK is a key member in the RAS/RAF/MEK/ERK pathway, which regulates several key cellular activities including proliferation, differentiation, migration, survival and angiogenesis. Dysregulation of this pathway frequently occurs in many types of cancer, in particular through mutations in BRAF, KRAS and NRAS. Currently, the drug is in Phase III stage of its development for the treatment of Neurofibromatoses. HLX-1502: Healx Limited HLX-1502 is an investigational, orally administered small molecule drug developed by Healx for treating Neurofibromatosis Type 1 (NF1), a rare genetic disorder marked by tumor growth along nerves. HLX-1502 was discovered using Healx's proprietary AI platform, which accelerates the identification of potential drug candidates. The therapy has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration, underscoring its potential significance for the NF1 community. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Neurofibromatosis Type 1. PAS-004: Pasithea Therapeutics Corp. PAS-004 is a small molecule allosteric inhibitor of MEK 1/2, which are dual-specificity protein kinases, in the MAPK signaling pathway. The MAPK pathway has been implicated in a variety of diseases, as it functions to drive cell proliferation, differentiation, survival and a variety of other cellular functions that, when abnormally activated, are critical for the formation and progression of tumors, fibrosis and other diseases. MEK inhibitors block phosphorylation (activation) of extracellular signal-regulated kinases (ERK). Currently, the drug is in the Phase I stage of its development for the treatment of Neurofibromatosis Type 1. The Neurofibromatoses Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Neurofibromatoses with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neurofibromatoses Treatment. Neurofibromatoses Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Neurofibromatoses Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neurofibromatoses market Stay informed about the Neurofibromatoses pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Neurofibromatoses Unmet Needs Neurofibromatoses Companies Shanghai Fosun Pharmaceutical, Healx Limited, Pasithea Therapeutics Corp., NFlection Therapeutics Inc., Infixion Bioscience and others. Neurofibromatoses Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Neurofibromatoses Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Transform your understanding of the Neurofibromatoses Pipeline! See the latest progress in drug development and clinical research @ Neurofibromatoses Market Drivers and Barriers, and Future Perspectives Scope of the Neurofibromatoses Pipeline Report Coverage- Global Neurofibromatoses Companies- Shanghai Fosun Pharmaceutical, Healx Limited, Pasithea Therapeutics Corp., NFlection Therapeutics Inc., Infixion Bioscience and others. Neurofibromatoses Pipeline Therapies- Trametinib, dabrafenib, bevacizumab, everolimus, Siltuximab, and others. Neurofibromatoses Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Neurofibromatoses Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Stay Ahead in Research-Access the Full Neurofibromatoses Pipeline Analysis Today! @ Neurofibromatoses Drugs and Companies Table of Contents Introduction Executive Summary Neurofibromatoses: Overview Pipeline Therapeutics Therapeutic Assessment Neurofibromatoses– DelveInsight's Analytical Perspective Late Stage Products (Phase III) FCN-159: Shanghai Fosun Pharmaceutical Drug profiles in the detailed report….. Mid Stage Products (Phase II) HLX-1502: Healx Limited Drug profiles in the detailed report….. Early Stage Products (Phase I) PAS-004: Pasithea Therapeutics Corp. Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Neurofibromatoses Key Companies Neurofibromatoses Key Products Neurofibromatoses- Unmet Needs Neurofibromatoses- Market Drivers and Barriers Neurofibromatoses- Future Perspectives and Conclusion Neurofibromatoses Analyst Views Neurofibromatoses Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
National Post
10 hours ago
- National Post
IKS Health Announces Transformational Partnership with Western Washington Medical Group through Strategic Investment in Managed Service Organization
Article content DALLAS — IKS Health, a global leader in care enablement solutions supporting clinicians, staff and patients throughout the care journey, is pleased to announce a transformative expansion of its partnership with Western Washington Medical Group (WWMG), a leading independent multispecialty healthcare organization in Washington state. Article content IKS Health will make a strategic investment in a newly established management services organization (MSO) that will oversee all nonclinical operations of WWMG, including revenue cycle management, clinical documentation, HR, IT and finance. The clinical operations will continue to reside within WWMG, allowing for a clear separation of clinical and administrative functions. Article content Article content As part of this expanded partnership, IKS Health will support WWMG through the newly formed MSO, helping the medical group improve performance across both fee-for-service and value-based care models. By addressing key administrative and operational functions, IKS will position WWMG to better manage risk-based populations, reduce friction in care delivery and improve financial sustainability and patient outcomes. Article content This support will be powered by IKS Health's comprehensive, AI-enabled care enablement platform. WWMG will gain access to advanced revenue cycle management, clinical documentation through the Scribble Suite's ambient scribing solution and a patient engagement hub driven by a patent-pending AI algorithm that predicts and reduces no-shows while improving communication across the care journey. Additional services include chart reviews, document management and care coordination. Article content 'Our work with IKS Health has resulted in streamlined operations and increased efficiencies, leading us to expand our partnership and further position us for growth and, most importantly, for providing excellent patient care,' said David Russian, M.D., CEO of Western Washington Medical Group. 'This strategic partnership with IKS Health will create transformational value for WWMG with a self-sustaining model for independent medicine that benefits all stakeholders — clinicians, patients and the communities that we serve.' Article content 'Our initial investment of substantial capital into the MSO reflects our strong conviction in the long-term potential of this partnership,' said Joe Benardello, co-founder and chief growth officer at IKS Health. 'The investment will be used to grow WWMG's physician base and expand its primary care capacity. When combined with the operational efficiencies driven by the IKS Health platform, it lays the foundation for scalable and sustainable growth.' Article content 'This partnership marks a pivotal step in IKS's journey to lead the strategic transformation of healthcare,' said Sachin K. Gupta, founder and CEO of IKS Health. 'It moves us meaningfully up the value chain, well beyond commoditized point solutions, and creates a scalable and replicable path to growth. By enabling a sustainable model for physician aggregation that delivers on the quadruple aim, we're not only unlocking two powerful pools of economic value (revenue from the IKS platform and long term value from the MSO growth) — we're also deepening the moat around our Care Enablement Platform and reinforcing our long-term relevance in an increasingly dynamic healthcare landscape.' Article content About Western Washington Medical Group Article content Western Washington Medical Group (WWMG) is a team of over 100 providers in 20+ specialty areas serving patients and their families in the north Puget Sound region of Washington State. Their providers are owners of the company, and they live and work in the communities that they serve. For over 30 years, it's been WWMG's mission to provide clinicians the freedom to practice medicine with compassion, in the best interest of their patients and community. Learn more at Article content About IKS Health Article content IKS Health takes on the chores of healthcare — spanning administrative, clinical, and operational burdens — so that clinicians can focus on their core purpose: delivering great care. Combining pragmatic technology and dedicated experts, IKS Health enables stronger, financially sustainable enterprises. IKS Health's Care Enablement Platform delivers data-driven value and expertise across the care journey, and IKS Health is a partner for clinician enterprises looking to effectively scale, improve quality, and achieve cost savings through forward-thinking solutions. Founded in 2006, IKS Health's global workforce supports large health systems across the United States. For more information on IKS Health and its solutions, please visit Article content Article content Article content Article content Article content Article content
